• Photonics West
  • 2018 Onsite News
  • BiOS
  • LASE
  • OPTO
  • Photonics West Exhibition
  • BiOS Expo
  • Industry Events
  • Courses
  • Hotels
  • Travel to San Francisco
  • Photonics West Sponsors
  • BiOS Expo Sponsors
  • For Authors and Presenters
  • For Chairs and Committees
  • For Photonics West Exhibitors
  • For BiOS Expo Exhibitors
Print Page
Email Page
27 - 28-January 2018
San Francisco, CA, United States


375 Saxonburg Blvd
Saxonburg, PA
United States
Company Description
Featured Product: Qomo Lasers: II-VI to introduce lasers ideal for Flow Cytometry & Confocal Fluorescence Microscopy

II-VI Incorporated, a global leader in engineered materials and opto-electronic components is a vertically integrated manufacturing company that develops innovative products for diversified applications in the industrial, optical communications, military, life sciences, semiconductor equipment, and consumer markets. Headquartered in Saxonburg, PA, with research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, visit www.ii-vi.com
24 January 2018
II-VI Incorporated Announces QOMO Laser Head Series for Biomedical Instruments
PITTSBURGH, Jan. 18, 2018 (GLOBE NEWSWIRE) -- II‐VI Incorporated (NASDAQ:IIVI), a leader in laser subsystems, today announced the introduction of its new compact, low noise QOMO laser head series for analytical instruments in life sciences, including for flow cytometers, confocal microscopes and bio-medical imaging applications.

Improvements in medical research, clinical diagnosis and treatment outcomes rely on the wide availability of biomedical instruments that produce accurate test results rapidly and cost effectively. The extremely stable, low noise, optical output power of II-VI’s QOMO laser head series enhances the measurement sensitivity of next generation flow cytometers, enabling greater accuracy and measurement throughput.

“The QOMO laser head series is a very cost effective solution due to its vertical integration of components manufactured in house, including semiconductor lasers, optics and thermo-electric coolers,” said Di Yang, General Manager, II-VI Suwtech. “The high measurement sensitivity of flow cytometers is critical for clinicians who need to accurately identify residual traces of target cells or markers.”

The QOMO series leverages II-VI’s well-established hardware and software platform with decades of field-proven reliability in optical networks. Moreover, the QOMO laser output spot size and beam geometry can be configured to match a wide variety of host analytical instrument designs. The first lasers from the QOMO series operate at 488 and 638 nm for dual-wavelength flow cytometry configurations and with output powers of up to 150 mW for confocal microscopy applications. The series will expand to cover additional wavelengths to enable simultaneous fluorescence analysis and other bio-medical imaging applications.

II-VI broad portfolio of products for flow cytometry includes optics and filters for fluorescence spectroscopy in the visible and ultraviolet wavelength ranges, as well as sheath cells and precision air and fluid temperature control systems based on thermo-electric coolers.

II-VI will showcase its QOMO laser head at SPIE Photonics West BiOS, Jan. 27-Feb. 1, 2018, in San Francisco, CA, Booth # 8725.
24 January 2018
II-VI Incorporated Launches Ultraviolet Fluorescence Filters for Biomedical Instruments
PITTSBURGH, Jan. 17, 2018 (GLOBE NEWSWIRE) -- II‐VI Incorporated (NASDAQ:IIVI), a leading provider of high-performance optics and coatings, today announced the commercial availability of a complete line of ultraviolet (UV) fluorescence filters for life sciences and biomedical instrumentation including flow cytometry, sequencing and imaging platforms.

Critical advances in cancer biology, infectious diseases and immunology have driven the development of new fluorochromes and high-performance optical systems that operate in the UV spectrum. II-VI’s UV fluorescence filters feature spectral profiles with high transmission, steep slopes and deep out of band blocking to enable maximum instrument sensitivity.

“II-VI continuously advances the state-of-the-art in thin-film technology to deliver very high-performance optics and coatings that enable next-generation fluorescence spectroscopy analytical instruments,” said Guanglong Yu, Vice President, R&D, II-VI Photop. “Our new family of ultraviolet filters extends our existing portfolio of visible and infrared filters that have been designed into a growing number of applications in the biomedical optics market.”

The optical filter product line for fluorescence spectroscopy includes excitation and emission filters as well as dichroic beam splitters. Single band and multi-band designs are available over a wide spectral range from UV to NIR. UV filters are available in the 200 to 400 nm wavelength band, in various dichroic or bandpass designs.

These new filters complement II-VI’s portfolio of products and solutions for spectroscopy and life sciences that includes narrow linewidth laser diodes, diode pumped solid state (DPSS) lasers, multi-colored lasers systems, gratings, flow cells and custom assemblies, as well as precision air and fluid temperature control systems based on thermo-electric coolers.

II-VI will showcase its broad portfolio of products for fluorescence spectroscopy at SPIE Photonics West BiOS, Jan. 27-Feb. 1, 2018, in San Francisco, CA, Booth # 8725.
24 January 2018
II-VI Incorporated Announces ISO 13485 Certification of Dallas Site to Design and Manufacture FDA Approved Biomedical Assemblies
PITTSBURGH, Jan. 16, 2018 (GLOBE NEWSWIRE) -- II-VI Incorporated (NASDAQ:IIVI), today announced that its product development center in Dallas, Texas has received ISO 13485 certification to support the design and manufacture of FDA approved biomedical assemblies.

Rapid advances in life sciences are driving the growing demand for specialized equipment from certified design centers and factories. II-VI’s ISO 13485 certification at its Dallas site marks the successful implementation of a comprehensive quality management system to support the design and manufacture of medical devices and systems for FDA approved equipment.

“This certification is a part of II-VI’s strategy to leverage our thermal management and mechanical design expertise to provide FDA approved biomedical assemblies to our customers,” said Kevin MacGibbon, General Manager, II-VI Marlow. “II-VI’s broad portfolio of materials, components and subsystems enable a wide range of biomedical equipment including PCR systems, blood analyzers, reagent chillers, as well as injury treatment and dental systems.”

II-VI provides optimum thermal management solutions for applications in life sciences, including genetic analysis, immunoassay, pharmaceutical development, clinical diagnostics, food analysis, agricultural development, environmental analysis, industrial hygiene and identification of bio-threats. II-VI’s broad array of thermal management solutions includes precision systems for thermal cycling, temperature stabilization, as well as air and fluid temperature control.

II-VI’s design lab ensures product development of the highest quality by conducting extensive performance and reliability tests, including mechanical integrity and endurance tests. II-VI’s thermal engines can include thermoelectric modules, cold plates, heat sinks, thermal interface materials, sensors and fans. II-VI also offers a broad portfolio of lasers and optics for applications in life sciences, such as for fluorescence spectroscopy and confocal microscopy.

II-VI will be exhibiting at SPIE Photonics West BiOS, Jan. 27-Feb. 1, 2018, in San Francisco, CA, Booth # 8725.
15 August 2017
Qomo Lasers
II-VI to introduce lasers ideal for Flow Cytometry & Confocal Fluorescence Microscopy:
- 488nm and 638nm
- Powers of 10-150mW, high power stability
- Ultra-low RMS noise, high polarization extinction ratio, & high beam quality
- Compact form factor, integrated driver & temperature control
Search Open Calls
Enter keywords to find conferences with open calls for papers and submit an abstract.